Botox versus tacrolimus for mild to moderate psoriasis
Treatments studied
Part of Skin clinical trials.
This study compares two treatments for mild to moderate psoriasis: Botox injections and a tacrolimus ointment (a topical medicine that calms the immune system). If you qualify, you may get one of these treatments to see which is more effective and safe for your skin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a mild to moderate form of psoriasis (a skin condition that causes red, scaly patches) that affects less than 10% of your body.
- You are at least 3 months past any psoriasis pills or light therapy, and at least 4 weeks past any psoriasis creams.
- You do not have a severe form of psoriasis (like pustular or erythrodermic).
- You do not have a nerve or muscle disease, or a history of epilepsy.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a proactive approach (adjusting drug levels based on regular blood tests) versus the usual way of using biologics for psoriasis. It helps see if active monitoring can improve treatment while keeping you safe.
This study compares two prescription creams, tacrolimus and crisaborole, to see which works better and is safer for treating mild to moderate eczema over 8 weeks. Both creams are applied to the skin and are alternatives to steroids.
This study compares two treatments for vitiligo: narrowband UVB light therapy combined with either tacrolimus ointment or calcipotriol ointment. It aims to see which combination works better and is safer for people with stable, limited vitiligo.
This study compares two creams for treating mild to moderate eczema in children: crisaborole 2% and tacrolimus 0.1%. It aims to see which one is more effective and safe for your child.
This study compares two oral pill treatments—methotrexate and tofacitinib—for people with chronic plaque psoriasis that is moderate to severe and hasn't responded well to creams. The goal is to see which pill works better at clearing skin.
This study compares two medications, methotrexate and tofacitinib, to see which works better for chronic plaque psoriasis in adults with moderate to severe symptoms. If you've tried creams that didn't help enough, you may be eligible.
Hear when a new Psoriasis Vulgaris trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.